{"id":49,"date":"2024-02-08T09:45:05","date_gmt":"2024-02-08T08:45:05","guid":{"rendered":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/?page_id=49"},"modified":"2025-09-25T13:51:45","modified_gmt":"2025-09-25T11:51:45","slug":"journal-club","status":"publish","type":"page","link":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/acciones-de-la-catedra\/long-acting\/journal-club\/","title":{"rendered":"<span lang=\"es\">(Espa\u00f1ol) Journal Club<\/span>"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/catedraenfermedadesinfecciosas.umh.es\/files\/2024\/04\/virus3.png&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|700|||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;42px&#8221; text_text_shadow_style=&#8221;preset5&#8243; text_text_shadow_blur_strength=&#8221;1.46em&#8221; text_text_shadow_color=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center\">C\u00e1tedra de Enfermedades Infecciosas y<\/p>\n<p style=\"text-align: center\">VIH\/SIDA<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; custom_margin=&#8221;|auto|-10px|auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.17.4&#8243; text_text_color=&#8221;#000000&#8243; text_font_size=&#8221;16px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; inline_fonts=&#8221;Adamina&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h3 style=\"text-align: center\"><span style=\"text-decoration: underline;font-family: Adamina;font-weight: normal\"><span style=\"color: #000000;text-decoration: underline\"><strong>JOURNAL CLUB\u00a0<\/strong><\/span><\/span><\/h3>\n<p><span style=\"text-decoration: underline;font-family: Adamina;font-weight: normal\"><span style=\"color: #000000;text-decoration: underline\"><strong><\/strong><\/span><\/span><\/p>\n<p style=\"text-align: center\">Art\u00edculos cient\u00edficos comentados en formato de texto. El comentario incluir\u00e1 los objetivos\/preguntas principales del art\u00edculo, los m\u00e9todos utilizados, los resultados obtenidos y las conclusiones del estudio. El comentario explicar\u00e1 espec\u00edficamente la validez de los m\u00e9todos y contextualizar\u00e1 los resultados y sus posibles implicaciones.<\/p>\n<p style=\"text-align: center\">\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/journal-club-3\/\"><strong>Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir\/Rilpivirine With Initial Viremia. <\/strong>Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F. <strong>Clinical Infectious Diseases<\/strong><\/a><strong><\/strong><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por F\u00e9lix Guti\u00e9rrez<\/span><\/li>\n<\/ul>\n<p style=\"text-align: left\">\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/journal-club-2\/\"><strong> PURPOSE-1 and PURPOSE-2 studies on the efficacy of lenacapavir <\/strong><\/a><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/journal-club-2\/\"><strong>(LEN) in HIV pre-exposure prophylaxis (PrEP). <\/strong>Linda-Gail Bekker, Moupali Das, <span>Colleen F.<\/span><span>Kelley<\/span>, Maribel Acevedo-Qui\u00f1ones<strong>. NEJM. <\/strong>December 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Sergio Padilla<\/span><\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/journal-club\/\"><strong>48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia. <\/strong>Hickey MD, Gistand N, Grochowski J et al<strong>. Clinical Infectious Diseases, <\/strong>November 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Javier Garc\u00eda<\/span><strong><\/strong><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><\/span><\/p>\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/octubre-2\/\"><strong>Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations <\/strong><span class=\"accordion-tabbed__tab-mobile  accordion__closed\"><\/span>Cassidy A. Gutner<i aria-hidden=\"true\" class=\"icon-mail_outline\"><\/i><span class=\"comma-separator\">,\u00a0<\/span><span class=\"accordion-tabbed__tab-mobile  accordion__closed\">Laurent Hocqueloux <\/span><strong>. <span>J Int AIDS, <\/span><\/strong>\u00a0November 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Miguel Garc\u00eda.<\/span><span style=\"text-decoration: underline\"><\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/octubre-1\/\"><strong>Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis. <\/strong>Raphael J. Landovitz<strong>.\u00a0 NEJM, <\/strong>October 2024.<\/a><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"color: #000000\"><u>Comentado por Enrique Bernal.<\/u><\/span><\/p>\n<\/li>\n<\/ul>\n<p><strong><span style=\"color: #1155cc\"><u><\/u><\/span><\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/junio-1\/\" target=\"_blank\" rel=\"noopener\" title=\"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial\"><strong>Switch to long-acting cabotegravir and rilpivirine in <\/strong><strong>virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.<\/strong>Cissy Kityo, Ivan K Mambule.\u00a0<strong> The Lancet, <\/strong>June 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Pere Domingo.<\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><\/span><\/p>\n<ul>\n<li><strong><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/mayo-2\/\" target=\"_blank\" rel=\"noopener\" title=\"\u201cCase Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial\u201d.\">Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.<\/a><\/strong><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/mayo-2\/\" target=\"_blank\" rel=\"noopener\" title=\"\u201cCase Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial\u201d.\">Gandhi M, Hill L. <\/a><strong><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/journal-club-marzo-2024-2\/\">Clinical Infectious Diseases<\/a><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/mayo-2\/\" target=\"_blank\" rel=\"noopener\" title=\"\u201cCase Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial\u201d.\">, <\/a><\/strong><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/mayo-2\/\" target=\"_blank\" rel=\"noopener\" title=\"\u201cCase Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial\u201d.\">\u00a0June 2024 .<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Vicente Estrada.<\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><\/span><\/p>\n<ul>\n<li><strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-05-comment-fgg_safety-of-teropavimab-and-zinlirvimab-with-lenacapavir-1-pdf\" target=\"_blank\" rel=\"noopener\">Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. <\/a><\/strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-05-comment-fgg_safety-of-teropavimab-and-zinlirvimab-with-lenacapavir-1-pdf\" target=\"_blank\" rel=\"noopener\">Joseph J Eron. Susan J Little<\/a><strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-05-comment-fgg_safety-of-teropavimab-and-zinlirvimab-with-lenacapavir-1-pdf\" target=\"_blank\" rel=\"noopener\">.\u00a0 Lancet HIV, <\/a><\/strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-05-comment-fgg_safety-of-teropavimab-and-zinlirvimab-with-lenacapavir-1-pdf\" target=\"_blank\" rel=\"noopener\">May 2024<\/a>.<\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Federico Garc\u00eda.<\/span><\/li>\n<\/ul>\n<ul>\n<li><strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-04-abril-2024-1-pdf\" target=\"_blank\" rel=\"noopener\" title=\"Real-world\">Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. <\/a><\/strong><a href=\"https-catedraenfermedadesinfecciosas-umh-es-files-2024-04-abril-2024-1-pdf\" target=\"_blank\" rel=\"noopener\" title=\"Real-world\">Paul Thoueillea, Susana Alves Saldanhaa, Fabian Schaller et al. <strong>The Lancet, <\/strong>April 2024<strong>.<\/strong><\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Miguel G\u00f3rgolas.<\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><\/span><\/p>\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/journal-club-marzo-2024-2\/\"><strong>Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modelling study<\/strong>. Sara Bettonte, Mattia Berton, Felix Stader et al. <strong>Clinical Infectious Diseases<\/strong>, March\u00a0 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por Mar Masi\u00e1.\u00a0<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/journal-club-marzo-2024-1\/\"><strong>Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis<\/strong>. Berend J van Welzen, Steven F L Van Lelyveld, Gerjanne Ter Beest et al. <strong>Clinical Infectious Diseases<\/strong>, March 2024.<\/a><\/li>\n<li><span style=\"text-decoration: underline\">Comentado por F\u00e9lix Guti\u00e9rrez.\u00a0<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;on|on|on&#8221; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][:es _i=&#8221;0&#8243; _address=&#8221;2.0.0.0&#8243; theme_builder_area=&#8221;post_content&#8221; \/][: _i=&#8221;1&#8243; _address=&#8221;2.0.0.1&#8243; theme_builder_area=&#8221;post_content&#8221; \/][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>C\u00e1tedra de Enfermedades Infecciosas y VIH\/SIDAJOURNAL CLUB\u00a0 Art\u00edculos cient\u00edficos comentados en formato de texto. El comentario incluir\u00e1 los objetivos\/preguntas principales del art\u00edculo, los m\u00e9todos utilizados, los resultados obtenidos y las conclusiones del estudio. El comentario explicar\u00e1 espec\u00edficamente la validez de los m\u00e9todos y contextualizar\u00e1 los resultados y sus posibles implicaciones. Viral Suppression Rates at 48 [&hellip;]<\/p>\n","protected":false},"author":2903,"featured_media":0,"parent":40,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Art\u00edculos cient\u00edficos comentados en formato de texto. El comentario incluir\u00e1 los objetivos\/preguntas principales del art\u00edculo, los m\u00e9todos utilizados, los resultados obtenidos y las conclusiones del estudio. El comentario explicar\u00e1 espec\u00edficamente la validez de los m\u00e9todos y contextualizar\u00e1 los resultados y sus posibles implicaciones. Se comentar\u00e1n 24 art\u00edculos anuales (2\/mes).<\/p><ul><li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/journal-club-marzo-2024-1\/\"><strong>Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis<\/strong>. Berend J van Welzen, Steven F L Van Lelyveld, Gerjanne Ter Beest et al. <strong>Clinical Infectious Diseases<\/strong>, 11 January 2024<\/a><ul><li>Comentado por F\u00e9lix Guti\u00e9rrez. Fecha Publicaci\u00f3n 8 de marzo de 2024.<\/li><\/ul><\/li><li><a href=\"https:\/\/catedraenfermedadesinfecciosas.umh.es\/acciones-de-la-catedra\/long-acting\/journal-club\/journal-club-marzo-2024-2\/\"><strong>Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modelling study<\/strong>. Sara Bettonte, Mattia Berton, Felix Stader et al. <strong>Clinical Infectious Diseases<\/strong>, 03 February 2024<\/a><ul><li>Comentado por Mar Masi\u00e1. Fecha Publicaci\u00f3n 15 de marzo de 2024.<\/li><\/ul><\/li><\/ul>","_et_gb_content_width":"","_links_to":"","_links_to_target":""},"_links":{"self":[{"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/pages\/49"}],"collection":[{"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/users\/2903"}],"replies":[{"embeddable":true,"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":0,"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/pages\/49\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/pages\/40"}],"wp:attachment":[{"href":"https:\/\/catedraenfermedadesinfecciosas.umh.es\/ca\/wp-json\/wp\/v2\/media?parent=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}